Nalan BABACAN AKGÜL, Birsen YÜCEL, Saadettin KILIÇKAP, Şafak ŞAHİN, Turgut KAÇAN, Ebru AKKAŞ ATASEVER, Yıllar OKUR, Mehmet Fuat EREN

Multipl primer malign neoplaziler: Cumhuriyet Üniversitesi verileri

Amaç. Onkolojik tedavilerdeki gelişmeler ve beklenen yaşam süresinin uzaması, tedavilerin geçyan etkileri ve ikinci kanserlerin gelişimi gibi sorunları da beraberinde getirmiştir. Aynı kişide,patolojik olarak tanımlanmış birden fazla malign tümörün varlığı multipl primer malign neoplazi(MPMN) olarak tanımlanmaktadır. Biz bu çalışmayla merkezimizde MPMN tanısı almışhastalarımızın demografik, patolojik ve klinik özelliklerini incelemeyi amaçladık. Yöntem.Merkezimize Ocak 2007 ile Ocak 2012 tarihleri arasında başvuran toplam 3108 kanser hastasınaait dosya bilgileri retrospektif olarak tarandı. Bulgular. Merkezimizde takip edilen 3108 kanserhastasının 38i (%1,2) MPMN tanısı almış idi. Bunların 21i (%55,3) kadın, 17si (%44,7) erkekti.Otuz yedi hastada iki primer neoplazi saptanırken, 1 hastada 3 primer neoplazi saptandı. Hastalarınortanca ikinci tümör tanı yaşı 60 (32-76) bulundu. Hastaların 6sı (%15,8) senkron, 32si (%84,2)metakron olarak MPMN tanısı almıştı. İki tanı arası geçen ortanca süre 40 aydı (0-372 ay).Hastalardaki en sık ilk primer tümör jinekolojik tümörler (10 hasta, %26,3) iken, en sık ikinciprimer tümör meme kanseri (7 hasta, %18,4) idi. En sık tümör birliktelikleri ise sırasıyla:jinekolojik tümörler-meme kanseri (5 hasta, %13,1), jinekolojik-jinekolojik tümörler (3 hasta,%7,9), sarkom-meme kanseri (3 hasta, %7,9), baş boyun tümörleri-akciğer kanseri (3 hasta, %7,9),üriner sistem-üriner sistem tümörleri (3 hasta, %7,9) şeklindeydi. Sonuçlar. Sonuçlarımızliteratürr ile uyumludur. Kanser tanısı almış hastalar, olası ikinci kanserler, koruyucu önlemler vetarama hakkında bilgilendirilmeli ve şüpheli lezyonlarda biyopsiden kaçınılmamalıdır.

Multiple primary malignant neoplasms: Data of Cumhuriyet University

Aim. Developments in cancer treatment and longer anticipated life period have brought out lateside effects related to therapy and development of a second cancer. Multiple primary malignantneoplasms (MPMN) are described as pathological diagnosis of two or more independent primaryreportable neoplasms in an individual. In this study we aimed to investigate demographic,pathological and clinical features of patients with multiple primary cancers in our center. Method.From January 2007 to January 2012, medical files of totally 3108 cancer patients wereretrospectively screened. Results. Thirty-eight (1.2%) of 3108 cancer patients followed-up at ourcentre were diagnosed as MPMN. Of these patients, 21 (55.3%) was female, and 17 (45%) wasmale. While 37 patients were found to have two different primary malignant neoplasms, only onepatient had three different primary cancers. The median age at the initial time of second primarycancer was 60 years (32-76). Patients with MPMN were diagnosed as synchronous neoplasm insix patients (16%) and as metachronous neoplasm in thirty-two (84%) patients. The medianinterval between the first and second cancers was 40 months (0-372). The most common primarytumor was gynecological cancers (n=10; 26%) and the most common secondary cancer was breastcancer (n=7; 18%). The most common cancer couplings were gynecological-breast cancer (n=5;13%), gynecological-gynecological cancer (n=3; 8%), sarcoma-breast cancer (n=3; 8%), head andneck-lung cancer (n=3; 8%), and urinary-urinary system cancer (n=3; %8), respectively.Conclusion. Our results comply with the literature. Patients with cancer should be informed byphysicians about development of secondary neoplasm, cancer prevention and screening. Cliniciansshould not hesitate from biopsy in suspected lesions.

PDF

___

1. Warren S, Gates O. Multiple primary malignant tumors: A survey of the literature and a statistical study. Am J Cancer 1932; 16: 1358-414.
2. Vaamonde P, Martín C, del Río M, LaBella T. Second primary malignancies in patients with cancer of the head and neck. Otolaryngol Head Neck Surg 2003; 129: 65-70.
3. Spratt JS Jr, Hoag MG. Incidence of multiple primary cancers per man-year of follow up: 20-year review from the Ellis Fischel State Cancer Hospital. Ann Surg 1966; 164: 775-84.
4. Hajdu SI, Hajdu EO. Multiple primary malignant tumors. J Am Geriatr Soc 1968; 16: 16-26.
5. Berge T, Cederqvist L, Schönebeck J. Multiple primary malignant tumours. An autopsy study of a circumscribed population. Acta Pathol Microbiol Scand 1969; 76: 171-83.
6. Lee TK, Myers RT, Scharyj M, Marshall RB. Multiple primary malignant tumors (MPMT): study of 68 autopsy cases (1963-1980). J Am Geriatr Soc 1982; 30: 744-53.
7. Aydıner A, Karadeniz A, Uygun K, Tas S, Tas F, Disci R, Topuz E. Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms. Am J Clin Oncol 2000; 23: 364-70.
8. Office on Smoking and Health, a, Report of the Surgeon General. DHEW Publ No (PHS)79-50066. Washington D, U.S. Government, Printing Office; 1979.
9. Brinton LA, Blot WJ, Becker JA, Winn DM, Browder JP, Farmer JC Jr, Fraumeni JF Jr. A case-control study of cancers of the nasal cavity and paranasal sinuses. Am J Epidemiol 1984; 119: 896-906.
10. Kelsey JL, Hildreth NG. Breast and gynecology cancer epidemiology. Boca Raton, FL, CRC Press, Inc 1983.
11. Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury GJ, Mehta J, Powles R, Ashley S, Kuan A, Powles T. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000; 83: 91-4.
12. Chaplain G, Milan C, Sgro C, Carli PM, Bonithon-Kopp C. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 2000; 18: 2836-42.
13. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, Guerci A, Gratecos N, Rayon C, San Miguel J, Odriozola J, Cahn JY, Huguet F, Vekhof A, Stamatoulas A, Dombret H, Capote F, Esteve J, Stoppa AM, Fenaux P. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2123- 37.
14. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, Pinedo HM, Somers R. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12: 1063-73.
15. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487-97.
16. Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Høst H, Prior P, Karjalainen S, Neal F, Koch M, Band P, Choi W, Kirn VP, Arslan A, Zarén M, Belch AR, Storm H, Kittelmann B, Fraser P, Stovall M. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322: 1-6.
17. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745-51.
18. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18: 498-509.
19. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003 (Erişim tarihi 06 Aralık 2012).
20. Gursel B, Meydan D, Özbek N, Ozdemir O, Odabas E. Multiple Primary Malignant Neoplasms from the Black Sea Region of Turkey. J Int Med Res 2011; 39: 667-74.
21. Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003; 26: 79-83.
22. Ueno M, Muto T, Oya M, Ota H, Azekura K, Yamaguchi T. Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003; 8: 162-7.
23. Vyas JJ, Deshpande RK, Sharma S, Desai PB. Multiple primary cancers in Indian population: metachronous and synchronous lesions. J Surg Oncol 1983; 23: 239- 49.
24. Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P, Lacau-Saint-Guily J, Laugier A, Schlienger M. Synchronous and metachronous head and neck carcinomas. Cancer 1994; 74:1933-8.
25. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
26. Liu YY, Chen YM, Yen SH, Tsai CM, Perng RP. Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis. Lung Cancer 2002; 35: 189-94.
27. Weichert KA, Schumrick D. Multiple malignancies in patients with primary carcinomas of the head and neck. Laryngoscope 1979; 89: 988-91.
28. Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, Feld R, Shepherd FA, Johnson DH, Grant SC, Aisner J, Johnson BE. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997; 89: 1782-8.
29. DeVita VTL, Theodore S.; Rosenberg, Steven A.: Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology, 8th Edition edn. California; 2008.
30. Engin K. Cancers in multiple primary sites. Int Surg 1994; 79: 33-7.
31. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12: 20-37.